BCG vaccine
Enable an agent to recognise BCG vaccine, assess the identity and usability of a particular presentation or lot, and identify the evidence and authorisation needed for its handling and vaccination use.
Research draft, second pass
A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.
recalled by Codex without web access - no source was read
Researched by: Codex
Purpose and description
Enable an agent to recognise BCG vaccine, assess the identity and usability of a particular presentation or lot, and identify the evidence and authorisation needed for its handling and vaccination use.
BCG vaccine is a live attenuated bacterial vaccine derived from Mycobacterium bovis, used to prevent tuberculosis, with its most established protection being against tuberculous meningitis and disseminated tuberculosis in young children.
It can be Identify a preparation as BCG vaccine and associate it with the correct product, strain and lot records.; Compare vaccine and diluent identifiers against product-specific preparation instructions and flag unresolved mismatches.; Assess documented storage exposure and usable-life limits, referring uncertain excursions for qualified disposition.; Retrieve applicable vaccination guidance and surface product restrictions for an authorised clinician to assess.; Trace affected supply during a recall and record quarantine, return or disposal under the responsible procedure..
Distinguishing features
The preparation is identified as live attenuated BCG derived from Mycobacterium bovis, rather than an unrelated tuberculosis vaccine candidate.
The labelled intended use is vaccination; a BCG preparation labelled for intravesical treatment requires a neighbouring therapeutic-product model.
The preparation contains viable vaccine organisms, distinguishing it from purified protein derivative used in tuberculin testing.
A named BCG strain or manufacturer identifies a variant or product within this vaccine class, rather than a separate registry thing.
A lot number, container and expiry identify physical vaccine supply, rather than the abstract vaccine class or a record of its administration.
Scope
+ BCG vaccine identity, biological lineage and distinction between the vaccine class, licensed products and physical lots
+ Product-specific formulation, presentation, diluent and preparation requirements
+ Viable potency, batch release evidence and quality status
+ Storage, transport, reconstitution and remaining usable life
+ Vaccination purpose, product-authorised administration constraints and links to applicable guidance
+ Traceability, recall status and disposition of unused or compromised material
- Tuberculosis disease, diagnosis and treatment
- Individual vaccination eligibility, prescribing and clinical management
- Intravesical BCG products and bladder-cancer treatment protocols
- Mycobacterium bovis as an organism independent of its vaccine preparation
- Population immunisation programmes and their policy decisions
- Syringes, cold-chain equipment and other supporting devices as independently modelled things
Characteristics
- BCG strain or substrain
- Product-declared strain or substrain designation; unverified; unknown Connects the preparation to its biological lineage and prevents unsupported assumptions that all BCG products are interchangeable.
- Product and manufacturer identity
- Links to the named product, manufacturer and applicable authorisation record Determines which formulation, preparation instructions and release specifications apply.
- Labelled intended use
- Tuberculosis vaccination; another declared use requiring boundary review; unknown Separates vaccination presentations from other preparations bearing the BCG name.
- Physical presentation
- Product-declared dosage form, container type and single-dose or multidose presentation Controls preparation requirements, dose accounting and handling after opening.
- Viable potency
- Product-specified viable-count unit per labelled dose or volume, with assay method and acceptance range Records biological potency without treating mass, nominal organism count and viable count as equivalent.
- Required diluent
- Link to the product-designated diluent and required reconstitution volume in mL Supports verification that a proposed diluent and volume match the specific vaccine presentation.
- Labelled dose and route
- Product- and recipient-category-specific labelled volume in mL and administration route Prevents instructions from one product or recipient category being applied indiscriminately to another.
- Storage and exposure requirements
- Product-specific temperature limits in °C, light protection and other labelled handling conditions Provides the criteria against which documented storage and transport exposure can be assessed.
- Preparation state
- Unopened; opened; reconstituted; partly used; discarded; unknown Changes the applicable handling instructions and usable-life clock.
- Usable-life limits
- Labelled expiry date and applicable time after opening or reconstitution in minutes or hours Supports calculation of a discard deadline using the correct product instructions.
- Quality and disposition status
- Released; awaiting verification; quarantined; recalled; expired; rejected; discarded Distinguishes physical possession of vaccine from evidence that the supply is available for authorised use.
- Lot provenance
- Links to manufacturer lot, supplier, release evidence and custody records Enables authenticity checks, recall matching and investigation of suspected defects.
Where this came from
wikidata · CC0 1.0
Drafted structure
Bundle to layer to finding to question, as the second pass will find it: 6 bundles · 11 layers · 19 findings · 31 questions.
BCG identity and boundaries Establishes which biological preparation and intended-use sense the registry entry covers.
The BCG name spans vaccine lineages, commercial presentations and therapeutic uses that must not be conflated.
Biological identity
Connects the vaccine preparation to its declared BCG lineage.
Strain lineage evidence
Record the declared BCG strain or substrain and the evidence connecting it to the named vaccine product.
- How does the product documentation identify its BCG strain or substrain? definition
- Which manufacturer or regulatory document establishes that lineage for this presentation? provenance
Intended use and instance boundaries
Separates vaccine identity from related BCG therapies, diagnostic reagents and physical instances.
Vaccination product classification
Use intended-use evidence to place a preparation within the vaccine class and retain product and lot distinctions beneath it.
- Does the label identify this preparation for vaccination, intravesical treatment or another use? boundary
- Does the record describe the vaccine class, a named product, a lot or an individual container? boundary
Viable preparation and quality Captures the formulation and quality evidence relevant to a vaccine containing live organisms.
BCG usability depends on a defined biological preparation and satisfactory quality evidence, which appearance alone cannot establish.
Formulation and presentation
Identifies the supplied dosage form, container and declared constituents.
Declared vaccine composition
Record product-specific composition and presentation without generalising one manufacturer's formulation to all BCG vaccines.
- What dosage form, excipients and container presentation does the applicable product document declare? definition
- Which components are supplied with this presentation, and which must be sourced separately under its instructions? boundary
Potency and release
Relates viable potency and required quality controls to a specific product and lot.
Lot quality evidence
Associate the lot with applicable viable-potency specifications and release evidence, keeping unavailable results explicit.
- What viable-potency range, reporting unit and assay basis apply to this product? measurement
- What evidence establishes that this lot satisfied the required quality controls and was released? provenance
Preservation and reconstitution Tracks how storage exposure and preparation change the usability of BCG vaccine supply.
A live vaccine's labelled expiry is insufficient to judge usability after compromised storage or reconstitution.
Storage exposure
Compares custody and exposure history with product-specific preservation requirements.
Preservation evidence
Record applicable storage conditions, observed exposures and unresolved gaps requiring disposition.
- What temperature, light and other exposure limits apply before and after preparation? measurement
- Do custody records show an excursion or missing interval, and who may decide its effect on usability? action
Diluent and use clock
Controls the transition from supplied presentation to prepared vaccine.
Reconstitution compatibility and deadline
Link the required diluent and preparation event to the applicable storage conditions and discard deadline.
- Which diluent identity and volume are explicitly designated for this vaccine presentation? definition
- What preparation timestamp and product-specific rule determine the latest permissible use time? measurement
- What disposition is required if the diluent, preparation time or preparation conditions cannot be verified? action
Vaccination purpose and use constraints Connects the physical vaccine to its intended protective role and authoritative constraints on use.
An agent must distinguish identifying usable stock from deciding whether and how a particular person should receive it.
Protective role and evidence
Frames protection claims by tuberculosis outcome, population and evidence context.
Bounded protection claims
Attach any protection claim to its specific outcome and population rather than representing BCG as uniformly preventing all tuberculosis.
- Which tuberculosis outcomes and recipient populations does each cited protection claim address? boundary
- Which authoritative evidence supports the claim, and what limitations does it report? provenance
Authorised administration interface
Exposes product instructions and clinical-policy dependencies without making individual treatment decisions.
Product and recipient use constraints
Link the presentation to labelled dose, route, recipient categories and restrictions requiring clinical review.
- What labelled route and dose volume apply to this product and the relevant recipient category? measurement
- Which contraindications, precautions and prior-vaccination or testing requirements must the authorised clinician assess under applicable guidance? action
- Which decisions belong to the recipient's clinical record rather than to the vaccine object? boundary
Traceability and disposition Maintains the evidence needed to locate, restrict and dispose of BCG vaccine supply.
Lot-specific defects, recalls and live biological remnants require traceable decisions throughout the supply lifecycle.
Supply and recall traceability
Connects physical containers to product, lot, supplier and current release or recall status.
Lot status verification
Retain identifiers and authoritative status evidence sufficient to recognise affected stock and prevent unsupported release.
- Which container identifiers connect this supply to its manufacturer lot and supplier records? provenance
- Which current notice or responsible authority determines whether this lot is released, restricted or recalled? provenance
Unusable material handling
Handles vaccine rendered unusable by expiry, preparation limits, damage or unresolved quality concerns.
Quarantine and biological disposal
Record why live BCG material leaves usable stock and link its final disposition to the applicable biological-waste procedure.
- What event requires this container to be quarantined, returned or discarded? action
- Which approved procedure governs residual live BCG vaccine, contaminated containers and spill material at this location? action
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Check these first
Recalled without web access and unsourced; every item is a lead to verify.
- This describes the vaccine category, not a particular manufacturer's product or an individual dose.
- Administration volume, viable bacterial content, storage and post-reconstitution limits require verification against the specific product label.
- Strain availability and national vaccination policies require current verification; the statements here are recalled knowledge, not source-checked research.
- Which of these check these first hold for the sense of BCG vaccine this model covers, and on what evidence? provenance
Kinds and varieties
Recalled without web access and unsourced; every item is a lead to verify.
- BCG Danish strain vaccines
- BCG Tokyo strain vaccines
- BCG Russian strain vaccines
- BCG Moreau strain vaccines
- Which of these kinds and varieties hold for the sense of BCG vaccine this model covers, and on what evidence? provenance
Identifiers and schemes
Recalled without web access and unsourced; every item is a lead to verify.
- WHO Anatomical Therapeutic Chemical classification - J07AN01 - Identifies BCG tuberculosis vaccines; BCG preparations for cancer immunotherapy have a separate classification.
- Which of these identifiers and schemes hold for the sense of BCG vaccine this model covers, and on what evidence? provenance
Standards and regulation
Recalled without web access and unsourced; every item is a lead to verify.
- WHO recommendations for the quality, safety and efficacy of BCG vaccines govern internationally recognized manufacturing and quality-control expectations.
- National medicines regulators authorize specific products and their approved labeling.
- National immunization authorities determine eligibility, timing and contraindications within vaccination programmes.
- Which of these standards and regulation hold for the sense of BCG vaccine this model covers, and on what evidence? provenance
Real-world use
Recalled without web access and unsourced; every item is a lead to verify.
- Routine infant tuberculosis vaccination in countries with substantial tuberculosis transmission.
- Selective vaccination of children at increased tuberculosis exposure risk in some low-incidence countries.
- Which of these real-world use hold for the sense of BCG vaccine this model covers, and on what evidence? provenance
Typical measurements
Recalled without web access and unsourced; every item is a lead to verify.
- Common intradermal administration volume - 0.05 or 0.1, depending on age and product - mL
- Common refrigerated storage temperature - 2-8 - °C
- Which of these typical measurements hold for the sense of BCG vaccine this model covers, and on what evidence? provenance
Failure modes and hazards
Recalled without web access and unsourced; every item is a lead to verify.
- Protection against pulmonary tuberculosis is variable, and vaccination does not reliably prevent infection.
- Local abscesses and suppurative lymphadenitis can occur; administration technique affects local complication risk.
- Rare disseminated BCG infection can occur, particularly in people with severe immune deficiencies.
- Heat, light exposure or improper handling after reconstitution can reduce vaccine viability and potency.
- Vaccination can affect tuberculin skin-test interpretation; a positive result cannot automatically be attributed to BCG.
- Which of these failure modes and hazards hold for the sense of BCG vaccine this model covers, and on what evidence? provenance
Regional variation
Recalled without web access and unsourced; every item is a lead to verify.
- Many higher-incidence countries use routine neonatal vaccination, whereas some lower-incidence countries use selective vaccination or do not routinely administer BCG.
- Available vaccine strains, manufacturers and presentations differ between countries.
- Age eligibility and policies concerning repeat vaccination differ between national programmes.
- Which of these regional variation hold for the sense of BCG vaccine this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Recalled without web access and unsourced; every item is a lead to verify.
- Mycobacterium bovis - The bacterial species from which BCG was attenuated; naturally occurring M. bovis can cause tuberculosis.
- Intravesical BCG - A BCG preparation administered into the bladder for cancer immunotherapy; its indication, route and dosing distinguish it from tuberculosis vaccination.
- Tuberculin purified protein derivative - A non-live diagnostic reagent used in skin testing, rather than a vaccine.
- Tuberculosis - The infectious disease targeted by vaccination, rather than the preventive biological product.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of BCG vaccine this model covers, and on what evidence? provenance
What the second pass must settle
- Does the existing world-model catalogue already cover BCG vaccine or an equivalent concept that this registry entry should link to?
- Which authoritative product records establish the strain, formulation, viable-potency specifications and permitted substitutions for the presentations to be represented?
- What exact storage, diluent, reconstitution and discard requirements apply to each included presentation, and how are uncertain excursions resolved?
- Which current jurisdiction-specific labels and vaccination policies govern dose, route, recipient restrictions and any differences between them?
- What evidence supports outcome- and population-specific protection claims, and which proposed non-tuberculosis effects should remain outside the established vaccination purpose?